Recent developments include positive dose optimization results for ProLectin-M advancing toward a Phase 3 trial, a commercial distribution agreement for a dietary supplement, and ongoing regulatory approvals and clinical trial progress.

• Bioxytran announced positive dose optimization results for ProLectin-M and advancement toward a Phase 3 trial, with the trial planned to start in Q3 2026 subject to funding [N1].
• The company entered a commercial distribution agreement with Khoury Medical LTD for A-SUQAR®, a dietary supplement containing Bioxytran’s proprietary PHGG formulation [S1].
• Bioxytran has received regulatory approvals from the FDA and India’s CDSCO for clinical trials of ProLectin-M and related drug candidates [S1].
• Phase 2 clinical trial results showed statistically significant earlier viral clearance and faster clinical improvement in COVID-19 patients treated with ProLectin-M, with no serious adverse events reported [S1].
• The company continues to develop its acellular oxygen carrier BXT-25, with successful animal trials demonstrating non-toxicity and full recovery in mice [S1].

Bioxytran’s positive Phase 2 clinical trial results for ProLectin-M demonstrate potential efficacy in reducing viral load and improving clinical outcomes in COVID-19 patients, with a favorable safety profile. The company’s advancement toward Phase 3 trials and regulatory approvals in the US and India support its clinical development progress. The novel acellular oxygen carrier BXT-25 shows promise in preclinical animal studies for treating ischemic stroke and hypoxia, addressing significant unmet medical needs. The company’s proprietary platform technologies and patent portfolio provide a foundation for developing multiple therapeutic candidates. Strategic partnerships and commercial distribution agreements, such as for its dietary supplement, may enhance market reach and revenue potential.

Bioxytran faces significant risks typical of clinical-stage pharmaceutical companies, including the uncertainty of clinical trial outcomes and regulatory approvals. The company’s financial position shows liquidity constraints with a low current ratio and ongoing net losses, indicating potential challenges in funding continued development and commercialization. The success of its drug candidates depends on further clinical validation, and failure to secure adequate funding could delay or halt progress. Competition from other therapies and evolving treatment standards may impact market acceptance. Intellectual property protection and the ability to license or commercialize products through third parties are critical and may pose challenges. The company’s limited operating history and reliance on key personnel add to execution risks.

Bioxytran’s moat is based on proprietary platform technologies involving galectin antagonists and co-polymer stabilized hemoglobin molecules, supported by a portfolio of patents and trade secrets developed over decades by its founder, Dr. David Platt. The company’s unique approach to glycovirology and oxygen delivery targets significant unmet medical needs in viral infections and hypoxia-related diseases. Its scientific and medical advisory boards provide expertise guiding clinical development. The company’s focus on novel carbohydrate drug design and its exclusive license for clinical monitoring technology (MDX Viewer) further differentiate its offerings. However, as a clinical-stage company, its moat is contingent on successful clinical development, regulatory approvals, and effective protection of intellectual property.

• Clinical Development Risk: Bioxytran’s drug candidates are in clinical or preclinical stages, and there is inherent uncertainty in successfully completing trials and obtaining regulatory approvals.
• Financial and Liquidity Risk: The company reported a net loss and has a low current ratio (0.16) and cash ratio (0.01) as of December 31, 2025, indicating potential liquidity constraints that may affect operations and development funding.
• Funding Risk: Bioxytran requires additional capital to advance clinical trials and commercialization efforts; failure to secure adequate funding could delay or impair development programs.
• Market and Competitive Risk: The pharmaceutical market is rapidly evolving and competitive; new treatments by others could reduce Bioxytran’s market opportunities.
• Intellectual Property Risk: Protection and enforcement of patents and proprietary technology are critical; litigation or inability to protect IP could adversely affect the company.
• Operational Risk: The company depends on retaining key executives and qualified personnel; loss of such individuals could disrupt operations and strategic direction.

• Bioxytran, Inc. is a clinical stage pharmaceutical company focused on developing platform technologies in Glycovirology, Hypoxia, and Degenerative Diseases to eliminate viruses and prolong lifespan using carbohydrate drug design [S1].
• The company was reorganized into Bioxytran in 2018 via reverse merger to focus on therapeutic drugs addressing Hypoxia, Degenerative Diseases, and antiviral treatments [S1].
• Bioxytran has four wholly owned subsidiaries specializing in drug development, manufacturing, intellectual property management, and clinical research in India [S1].
• The lead glycovirology drug candidate is ProLectin-M (PL-M), a galectin antagonist based on partially hydrolyzed guar gum (PHGG), designed to reduce viral load in COVID-19 patients [S1].
• Phase 2 clinical trial results showed statistically significant viral load reduction and faster clinical improvement in mild to moderate COVID-19 patients treated with ProLectin-M, with no serious adverse events reported [S1].
• The company has FDA and Indian CDSCO IND approvals for clinical trials of ProLectin-M and related drug candidates for COVID-19 and lung fibrosis [S1].
• Bioxytran is developing BXT-25, an Acellular Oxygen Carrier (AOC) based on camel hemoglobin stabilized with a co-polymer, intended for intravenous treatment of ischemic stroke and hypoxic conditions [S1].
• BXT-25 has been successfully manufactured in trial batches and tested in animal studies showing non-toxicity and full recovery in mice [S1].
• The company plans to advance BXT-25 through preclinical and clinical studies, aiming for FDA approval for stroke and other hypoxia-related indications [S1].
• Bioxytran's technology targets galectin-3 protein to block viral replication and modulate immune response, potentially applicable to multiple viral infections [S1].
• The company has a scientific and medical advisory board with leading experts guiding clinical trial programs [S1].
• Bioxytran's financial snapshot as of 2025-12-31 shows current assets of $513,465 and current liabilities of $3,249,894, resulting in a low current ratio of 0.16 and cash ratio of 0.01, indicating liquidity constraints [S1].
• Net loss for the year ended 2025-12-31 was $2,123,077 with basic and diluted EPS of -$0.02 [S1].
• The company announced positive dose optimization results for ProLectin-M and advancement toward a Phase 3 trial, with the Phase 3 trial planned to start in Q3 2026 subject to funding [N1][S1].
• Bioxytran entered a commercial distribution agreement for a dietary supplement containing its proprietary PHGG formulation in February 2026 [S1].